Opus Genetics VEGA-3 Phase 3 trial meets primary endpoint for presbyopia treatment

Opus Genetics, Inc.

27.2% of patients on drug achieved ≥15-letter DCNVA gain vs 11.5% placebo (p<0.0001) at 12h post-dose on Day 8.
Safety profile consistent with prior trials; no treatment-related serious adverse events reported.
No evidence of tachyphylaxis over the 6-week study period.
NDA submission to FDA planned for the second half of 2025.
Cash on hand expected to fund operations into H2 2026.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.